Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2{degrees}P-TIMI 50 Trial

Conclusions
Vorapaxar reduces peripheral revascularization in patients with PAD. This benefit of vorapaxar is directionally consistent across type of procedure and indication. (Trial to Assess the Effects of Vorapaxar [SCH 530348; MK-5348] in Preventing Heart Attack and Stroke in Patients With Atherosclerosis [TRA 2°P - TIMI 50] [P04737]; NCT00526474)

Source: Journal of the American College of Cardiology: Cardiovascular Interventions - October 23, 2016 Category: Cardiology Authors: Bonaca, M. P., Creager, M. A., Olin, J., Scirica, B. M., Gilchrist, I. C., Murphy, S. A., Goodrich, E. L., Braunwald, E., Morrow, D. A. Tags: Peripheral Source Type: research